High MET expression has been reported in bone metastasis: Knudsen et al. [15] reported higher MET expression in bone metastasis than in primary prostate tumors, using immunohistochemical analysis; and Previdi et al. performed in vivo studies and reported that treatment with tivantinib (a MET inhibitor) reduced bone metastasis progression and cancer cell-induced bone destruction with improved survival in breast cancer [16, 17]. Here, MET is linked to breast cancer.